AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Impaired Type I IFN Immunity Due to Autoantibodies or a Genetic Defect: a Prospective National Cohort

Recruitingn/aAges 18 Years - anyAllInstitut National de la Santé Et de la Recherche …
💬

In plain words

What the trial is, and whether it could suit you

The major role of human genetic factors in the immune response to infections is now well established, particularly for viral infections. In the context of the COVID-19 pandemic, the following results have identified 1) several inborn errors of immunity (IEI) affecting the response or production of type I interferons (type I IFNs) in around 4% of adult patients with severe clinical disease, and 2) the presence of type I IFN-neutralizing autoantibodies (auto-Abs) in around 15% of severe cases, and 20% of deaths. The investigators would like to carry out a longitudinal immunological and clinical follow-up study on a prospective cohort of patients with either a genetic defect affecting the type I IFN-dependent immune response, or anti-IFN-I auto-Abs, to monitor the incidence of infectious and/or autoimmune events in these individuals, the evolution of neutralizing power, and the kinetics of

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Age \>18 years * History of carrying 1) auto-Abs against type I IFNs or 2) IEI impairing the response to, or the production of, type I IFNs (IFN-I-IEI) * Affiliated to social security * Written informed consent Exclusion Criteria: * Participation to an interventional clinical trial on a pharmacological treatment * Clinical condition leading to life expectancy less than 1 year * Subject to a legal protection measure (safeguard of justice, curatorship, tutorship) * Individuals deprived of freedom
💊

What it tests

  • blood sample
📍

Where

9 sites
Cic Lille
Lille, France
LYON HCL
Lyon, France
Cic Montpellier
Montpellier, France
Cic Bichat
Paris, France
Cic Creteil
Paris, France
Cic La Salpetriere
Paris, France
Cic Necker
Paris, France
Cic St Louis
Paris, France

…and 1 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy